Quince Therapeutics Inc
QNCX
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.25M
Close$
$-0.20
101.2% downside
Current Fair Value
101.2% downsideOvervalued by 101.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.25 Million |
|---|---|
| Enterprise Value | $-12,503,450.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.8 |
| Beta | 1.37 |
| Outstanding Shares | 5,009,690 |
Return
| Return on Equity | -210.80% |
|---|---|
| Return on Assets | -124.09% |
| Return on Invested Capital | -316.07% |
Valuation & Multiples
| P/E Ratio | -0.15 |
|---|---|
| PEG | 0.04 |
| Price to Sales | - |
| Price to Book Ratio | 5.74 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.22 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.03 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-9.40
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Quince Therapeutics Inc
38 employeesCortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence genera...